Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

LSM change from baseline in SDAI components showed a trend for improvement with PF‐06651600 versus placebo throughout the 8‐week treatment period (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlin​elibr​ary.wiley.com/doi/10.1002/art.41316/​abstract ); statistical separation of PF‐06651600 from placebo was shown at week 8 for the TJC ( P = 0.008), week 6 for the PhGA score ( P = 0.017), and weeks 2, 4, 6, and 8 for the PtGA score (all P < 0.05); there were no differences for these components at other time points, or for the SJC at any time point.

also in 53,322 other papers